Company: RVRC
Filing Date: 2025-12-12
Form Type: S-1/A
Source: 0001213900-25-121070
Chunk: 61

Company: Revium Rx.
Filing Date: 2025-12-12
Form: S-1/A
Chunk 61
---
 retail
mark-up, mark-down or commissions and may not necessarily represent actual transactions. On December 3, 2025], the closing price of our
Common Stock was $0.52. Trading volume in our Common Stock has often been very limited. As a result, the trading price of our Common
Stock has been subject to significant fluctuations. There can be no assurance that a liquid market will develop in the foreseeable future.

We intend to apply to upgrade our Common Stock
to the OTCQB marketplace of the OTC Markets. Among the standard requirements to be eligible for the OTCQB, we must have a public float
of 10% of the total issued and outstanding shares and at least 50 beneficial shareholders each owning at least 100 shares. The Company
must also be required to file reports with the SEC. After the registration statement of which this prospectus is a part of is declared
effective by the SEC, we intend to apply to the OTCQB. Notwithstanding our belief that upon the effective date of this registration statement
our Common Stock will satisfy the admission requirements for the OTCQB and our intention to make application for quotation on the OTCQB
Market, we cannot assure you that our Common Stock will be quoted on the OTCQB tier.

Holders

As of December 4, 2025, there were 118 holders
of record of our Common Stock. The number of record holders does not include an indeterminate number of stockholders whose shares are
held by brokers in street name.

Dividend Policy

We have not paid any dividends since our incorporation
and do not anticipate the payment of dividends in the foreseeable future. At present, our policy is to retain earnings, if any, to develop
and market our products and implement our business plan. The payment of dividends in the future will depend upon, among other factors,
our earnings, capital requirements, and operating financial conditions.

<div align='center'>35

MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION

AND RESULTS OF OPERATIONS OF REVIUM RX. AND REVIUM RX LTD.</div>

The following discussion should be read in conjunction with our consolidated financial statements and notes thereto included herein. We caution readers regarding certain forward-looking statements in the following discussion and elsewhere herein and any other statement made by, or on our behalf, whether or not in future filings with the Securities and Exchange Commission. Forward-looking statements are statements not based on historical information and which relate to future operations, strategies